### Analysis:

Amgen’s Q2 2021 earnings call highlights strong financial performance and pipeline advancements. The company reported a 5% increase in revenues and 4% year-over-year non-GAAP EPS growth. Key highlights include:

- **Pipeline Advancements**: Amgen showcased progress in multiple therapeutic areas, including oncology, inflammation, and bone health.
- **Acquisitions and Partnerships**: The company announced several strategic acquisitions and partnerships, including Five Prime Therapeutics and Teneobio, which will strengthen its R&D capabilities.
- **Revenue Growth**: Amgen saw robust growth in key products such as Repatha, Otezla, and biosimilars.
- **Tax Dispute**: The company disclosed ongoing IRS tax disputes, which could impact future financial performance.

### Conclusion:

Amgen’s strong Q2 performance and pipeline advancements suggest a positive outlook for the company. However, the ongoing tax disputes and potential impact on operating margins could pose short-term risks. Overall, the stock is expected to see positive momentum in the near term, driven by the company’s strong financial performance and pipeline advancements.

**Rating: 1**